Compare Johnson & Johnson (JNJ) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Linde PLC — how do they compare? Johnson & Johnson trades at $252.45 (market cap $609.12B), while Linde PLC trades at $511.7 (market cap $237.29B). The key difference: Johnson & Johnson is far larger — about 2.6× Linde PLC's market cap, and Johnson & Johnson pays the higher dividend (2.12%). Which is the better fit depends on your goals.
| JNJ | LIN | |
|---|---|---|
Market Cap | $609.12B | $237.29B |
Volume | 6,156,228 | — |
Sector | Health | Basic Materials |
52-Week High | $267.24 | $546.64 |
52-Week Low | $163.70 | $389.38 |
Enterprise Value | $642.06B | $259.64B |
Dividend Yield | 2.12% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $253.04, up 1.23% today, with a bullish technical signal from moving averages and strong earnings beats in Q1 and Q2 2026. The company raised 2026 guidance, with revenue projected to exceed $100 billion, supported by robust profitability margins and a solid dividend track record. Recent news highlights institutional buying and analyst optimism following Q2 results.
Outlook remains positive with a consensus price target of $279.33, offering ~10% upside. Key risks include MedTech segment volatility and rising debt levels, but JNJ's diversified healthcare portfolio and AAA balance sheet provide stability for long-term investors amid market fluctuations.
Linde (LIN) trades at $513.07, down 1.47% on the day, with strong fundamentals including 20.44% net income margin and consistent earnings beats. The stock shows neutral technical signals with support at $514 and resistance at $525. Recent Q1 2026 results showed 10% EPS growth to $4.33, beating estimates, while revenue reached $8.78 billion. The company maintains robust cash flow generation with $10.35 billion from operations in 2025.
Outlook remains positive with 89% analyst buy ratings and $564.80 consensus price target, representing 10% upside. Key risks include rising debt-to-asset ratio (31.63% in 2025) and valuation concerns at 34x P/E. The dividend growth streak of 33 years and sustainability leadership provide stability amid industrial sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
